SCHEMBL4323979

SCHEMBL4323979

NC(=S)NN=Cc1cc(F)c(N2CC[C@H](NCc3c(Cl)cccc3Cl)C2)cc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMEM97 Q5BJF2 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
MAOB P27338 2/20 0.40
HTT P42858 5/20 0.37
LMNA P02545 3/20 0.37
MAPT P10636 3/20 0.37
RECQL P46063 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
RCE1 Q9Y256 1/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
KDM4E B2RXH2 2/20 0.37
GAA P10253 1/20 0.37
MPI P34949 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALDH1A1 P00352 4/20 0.36
ALOX12 P18054 3/20 0.36
KMT2A Q03164 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
HCRTR1 O43613 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4323973 1.00 TMEM97 (0.45) TMEM97SIGMAR1MAOBHTTLMNA
SCHEMBL4344669 0.97 TMEM97 (0.43) TMEM97SIGMAR1MAOBHTTLMNA
SCHEMBL4344671 0.97 TMEM97 (0.43) TMEM97SIGMAR1MAOBHTTLMNA
SCHEMBL4335731 0.97 TMEM97 (0.43) TMEM97SIGMAR1MAOBHTTLMNA
SCHEMBL4335730 0.97 TMEM97 (0.43) TMEM97SIGMAR1MAOBHTTLMNA
SCHEMBL4336927 0.95 TMEM97 (0.41) TMEM97SIGMAR1MAOBHTTLMNA
SCHEMBL4336923 0.95 TMEM97 (0.41) TMEM97SIGMAR1MAOBHTTLMNA
SCHEMBL4338115 0.91 TMEM97 (0.42) TMEM97SIGMAR1MAOBHTTLMNA
SCHEMBL4340441 0.91 TMEM97 (0.42) TMEM97SIGMAR1MAOBHTTLMNA
SCHEMBL4338112 0.91 TMEM97 (0.42) TMEM97SIGMAR1MAOBHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 TMEM97 784/4885SIGMAR1 948/4885MAOB 2762/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 TMEM97 720/4885SIGMAR1 776/4885MAOB 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.